SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sørensen, T L
Right arrow Articles by Sellebjerg, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sørensen, T L
Right arrow Articles by Sellebjerg, F
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Selective suppression of chemokine receptor CXCR3 expression by interferon-b1a in multiple sclerosis

T L Sørensen

The MS Clinic, Department of Neurology, University of Copenhagen, Glostrup, DK-2600 Copenhagen, Denmark, torbenls{at}dadlnet.dk

F Sellebjerg

The MS Clinic, Department of Neurology, University of Copenhagen, Glostrup, DK-2600 Copenhagen, Denmark

We studied the expression of chemokine receptors CCR1, CCR2, CCR3, CCR5, and CXCR3 on CD4 and CD8 positive T cells, and on CD14 positive monocytes in blood from 10 patients with relapsing-remitting multiple sclerosis (MS) at initiation of interferon (IFN)- ßtreatment, after 1 month and after 3 months of treatment. It was found that the expression of CXCR3 on CD4+ and CD8+ T cells was significantly reduced after 3 months of treatment. The expression of other receptors was unaltered. Since CXCR3 cells are enriched in cerebrospinal fluid (CSF), and are detected in lesion material in MS this may represent an important mode of action of interferon- ßin MS.

Key Words: chemokine receptors • chemokines • demyelinating disease • multiple sclerosis • neuroimmunology

Multiple Sclerosis, Vol. 8, No. 2, 104-107 (2002)
DOI: 10.1191/1352458502ms781oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Arch NeurolHome page
S. Cepok, H. Schreiber, S. Hoffmann, D. Zhou, O. Neuhaus, G. von Geldern, S. Hochgesand, S. Nessler, V. Rothhammer, M. Lang, et al.
Enhancement of Chemokine Expression by Interferon Beta Therapy in Patients With Multiple Sclerosis
Arch Neurol, October 1, 2009; 66(10): 1216 - 1223.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
I. Tsunoda, T. E Lane, J. Blackett, and R. S Fujinami
Distinct roles for IP-10/C XC L10 in three animal models, Theiler's virus infection, EA E, and MHV infection, for multiple sclerosis: implication of differing roles for IP-10
Multiple Sclerosis, February 1, 2004; 10(1): 26 - 34.
[Abstract] [PDF]

Home page
 Mult SclerHome page
D J Mahad, J Lawry, S J. Howell, and M N Woodroofe
Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse
Multiple Sclerosis, April 1, 2003; 9(2): 189 - 198.
[Abstract] [PDF]


Advertisement